outperform
initi coverag ioni pharmaceut outperform
rate price target solid base busi revenue-gener
asset broadli applic discoveri platform strateg partnership
illustr profit innov oxymoron believ offer
diversifi invest opportun within rnai sub-seg biotechnolog
well posit growth current portfolio commerci asset
increment valu inflect opportun develop pipelin note
complex busi model sever subsidiari partnership atyp
innovation-driven biotechnolog compani howev clinic commerci
valid technolog platform believ manag may well posit
make select invest potenti drive organ growth longer term
innov compon focus advanc discoveri technolog
early-stag pipelin strateg partnerships/collabor develop
subsequ commerci discoveri publicli
trade majority-own subsidiari develops/commerci medicin rare
diseas gener revenu royalti commerci product sale
payment partner servic
base busi revenue-gener asset view ionss commerci
portfolio solid base busi potenti contribut meaning
top line margin time three commerci asset portfolio
believ potenti gener diversifi revenu stream
tegsedi key contributor top line next five year
antisens oligonucleotid aso therapi aso short synthet strand
nucleic acid base pair length bind directli homolog rna
sequenc depend chemistri bind mode aso modul target
rna express sever way manag invest heavili enhanc ionss
platform improv potenc expand clinic util
profit innov oxymoron continu invest
pipelin technolog like strong balanc sheet abil gener
cash flow oper cash potenti continu
gener posit cfo believ well posit fund near-
term intern invest execut capit deploy activ
year price histori
target drug discoveri
compani
analyst certif import disclosur see disclosur
tegsedi us/eu revenu base patient
share grow thereaft peak share
waylivra eu revenu base patient
share includ contribut label expans fpl
probabl adjust
spinraza royalti reach peak
revenu contribut up-front mileston licens payment
exist collabor
oper expens consist
 sg expens grow thereaft
stronger expect launch tegsedi waylivra
posit readout clinic program lead pipelin
advanc mileston gener
exercis licens option collabor partner
solid base busi
asset broadli applic discoveri platform strateg
partnership illustr profit innov
oxymoron believ offer diversifi
rnai sub-seg
biotechnolog well posit growth
current portfolio commerci asset increment valu
inflect opportun develop pipelin
complex busi model sever subsidiari partnership
atyp innovation-driven biotechnolog compani
howev clinic commerci valid technolog
platform believ manag may well posit
make select invest potenti drive organ growth
long-term
ionis-httrx phase ole data huntington diseas
phase top-line result nafld/metabol
complic earli
akcea-apociii-lrx phase top-line result cardiovascular
diseas earli
akcea-apoa-lrx phase initi hypertriglyceridemia
ionis-maptrx phase data alzheim diseas
tegsedi waylivra commerci updat
new partnership announc licens decis
weaker expect launch tegsedi waylivra
neg readout clinic trial lead potenti program
suspens failur gener milestone/licens revenu
higher expect oper expens
target price base discount cash flow analysi model sale lead product candid ten-year period
assum termin valu base tail market product project period discount cash flow
use discount rate believ approxim compani weight averag cost capit base risk-fre rate
expect market return beta per bloomberg also model termin growth rate believ
reflect recur growth potenti offer discoveri develop platform
downsid risk price target includ weaker expect launch tegsedi waylivra neg readout
clinic trial lead potenti program suspens failur gener milestone/licens revenu higher expect oper
ioni pharmaceut inc commercial-stag biotechnolog compani
leverag proprietari antisens technolog platform develop rna interfer
rnai therapi treat variou rare neurodegen cardiometabol renal
condit well cancer autoimmun diseas busi model includ
core innov compon focus advanc discoveri technolog early-
stage pipelin strateg partnerships/collabor focus develop
subsequ commerci discoveri akcea therapeut
publicli trade major own subsidiari develops/commerci medicin
rare diseas gener revenu royalti commerci product sale
payment partner servic provid exhibit
gener commerci revenu spinraza royalti well sale
waylivra tegsedi approv treat rare diseas exhibit
ionss clinic pipelin includ partner wholli own asset address
broad rang indic exhibit
manag alreadi highlight sever clinic regulatori catalyst
exhibit import view phase data
potenti akcea-apociii-lrx licens decis novarti note
divers ionss pipelin partnership may provid sever valu driver
solid base busi revenue-gener asset
view ionss commerci portfolio solid base busi potenti
contribut meaning top line margin time three commerci
asset portfolio believ potenti gener diversifi revenu
stream tegsedi key contributor top line next five year exhibit
tegsedi uptak thesi
tegsedi inotersen antisens oligonucleotid aso inhibitor human transthyretin
ttr product approv treatment stage polyneuropathi associ
hereditari transthyretin hattr amyloidosi tegsedi approv sever
countri market us/eu
preliminari address market opportun estim tegsedi us/eu
exhibit estim near-term address opportun base diseas
preval estim provid manag howev note mani expert
claim diseas underdiagnos actual preval higher
revenu potenti geographi exclud
wac price per manag pricerx us eu convert gbp usd
estim royaltiestegsediwaylivraotheruseuropehattr amyloidosi pn price per per per patient per gross-to-net price per patient per amyloidosi opportun outperform
transthyretin amyloidosi progress fatal condit aris mutat
ttr gene encod transthyretin plasma transport protein produc liver
ttr mutat caus dissoci ttr tetram singl protein monom
result amyloidosi aggreg insolubl low molecular weight protein fibril
tissu amyloid plaqu accumul
cardiomyopathi weaken heart muscl and/or neuropathi nerv cell damag
depend particular ttr mutat exhibit mean durat diseas
diagnosi death approxim year
exhibit overview hattr amyloidosi
sourc gertz et al journal american colleg cardiolog pmid uptod treatment amyloid
cardiomyopathi treatment underli protein fold disord
model us/eu revenu grow separ
model royalti revenu latin american sale begin grow
exhibit us eu revenu base increas rate diagnosi
current patient share reach preval popul
grow thereaft
hattr polyneuropathyhattr cardiomyopathycommon ttr progress peripher neuropathi affect nerv fiber larg small atrial arrythmiaprogress heart wall skin biopsyendomyocardi biopsyavail transplanttegsedionpattrodiuret agentstafamidi sharerevenu estim useuroyaltiespati share ioni pharmaceut
conserv waylivra
waylivra approv eu adjunct diet genet confirm famili
chylomicronemia syndrom fc patient high risk pancreat receiv
complet respons letter us manag indic
discuss fda regard next step model waylivra commerci
eu latin america
estim waylivra eu fc market opportun potenti
grow ions/akca success achiev label expans treat patient
famili partial lipodystrophi fpl exhibit note european regul
grant orphan drug design waylivra fc fpl
fpl preval rate per chiquett diabet metabol syndrom obes target therapi
wac price per manag commentari per syring euro usd convers rate
oppenheim research compani materi factset european union chiquett diabet metabol syndrom
obes target therapi
fc rare genet driven form hyperlipoproteinemia type lipodystrophi
lipid storag disord character hypertriglyceridemia elev level
serum triglycerid tg even fast condit aris due defici
lipoprotein lipas lpl encod sever gene promot proper lpl function
includ lmna lpl-driven
increas tg usual normal mg/dl increas risk
cardiovascular diseas fatal pancreat fc patient suffer chronic acut
pancreat direct result chronic pancreat inflamm relat high tg
waylivra target inhibitor lpl base evid suggest inhibit
stimul lpl activ reduc tg waylivra target
genet driver fc
protein synthes liver key regul tg metabol
compon triglycerid rich lipoprotein trl low-dens lipoprotein
hdl chylomicron multipl
mechan affect tg level includ inhibit
lipoprotein lipas key enzym drive lipoprotein hydrolysi promot
gaudet et al new england journal medicin
larosa jc et al biochem biophys research commun
hepat vldl secret and/or chylomicron format suppress clearanc
trl remnant product lipoprotein lipas
model eu revenu grow exhibit
waylivra revenu estim includ fc commerci sale eu royalti
latin american sale begin also includ risk-adjust revenu
approv commerci waylvira eu fpl begin fpl
rare diseas involv abnorm distribut adipos tissu mani patient fpl
elev tg level increas pancreat risk
royalti commerci sale waylivra latin america estim royalti rate
spinraza nusinersen antisens oligonucleotid aso approv sever
countri treatment spinal muscular atrophi sma children adult
commerci spinraza approv market receiv
royalti net sale
launch estim sma preval us eu japan
patient combin exhibit recent increas estim
address market patient
exhibit sma preval major commerci region initi biogen estim
 sack current opinion lipidolog
note spinraza experienc strong patient revenu growth global exhibit
row patient contribut meaning overal growth trend
exhibit spinraza histor revenu patient uptak
model global royalti grow exhibit
base royalti rate assumpt near-term follow declin
longer term driven loss exclus patent expir
own proprietari discoveri platform develop aso therapi aso
short synthet strand nucleic acid base pair length bind directli
homolog rna sequenc depend chemistri bind mode aso
modul target rna express sever way exhibit exampl aso
gapmer induc rnase h-mediat degrad transcript mutation-
specif manner modifi aso alter express steric hinder rna
bind protein result block translat protein express alter transcript
splice due broadli applic mechan action believ aso may
therapeut applic across divers rang diseas caus abnorm gene
product disease-caus protein
modifi protein increas protein
product may also treat diseas
target degrad disease-
caus rna toxic rna
evolv platform next-gen lica-aso
manag invest heavili enhanc ionss platform improv potenc
expand clinic util includ chemic optim improv potenc
reduc off-target effect exhibit addit conjug chemistri enabl
increas potenc improv stabil weekli dose vs daili w/ reduc inflammatori effect reduc off-target toxic increas potenc expand target abilityadministr rout subcutan inject intraven infus inhal topic intrathec subcutan inject intraven infus inhal topic intrathec oral
conjug molecul aso could promot enhanc uptak potenc
date develop lica asset target liver pancrea develop
liver-specif lica use n-acetylgalactosamin galnac conjug enrich
target aso liver exhibit improv overal potenc regardless
rna target exhibit
also develop lica target addit organ system includ
pancrea technolog exploit pancreat islet cell-specif express
receptor aso show islet cell-restrict uptak preclin mous
top schemat structur aso target bottom cell-restrict uptak lica- aso a/c
wild-typ b/c mice singl intraven dose
develop lica- version exist medicin specif tegsedi
waylivra numer lica asset pipelin
variou stage exhibit see follow page collect improv product
constitut signific portion clinic pipelin
exhibit pipelin breakdown gener /- lica
profit innov oxymoron
continu invest pipelin technolog like strong balanc
sheet abil gener cash flow oper cash
potenti continu gener posit cash flow oper exhibit believ
compani well posit fund intern invest near term
explor capit deploy activ opportunist share repurchas note
announc repurchas program novemb
exhibit oper balanc
licanon-licaassetpartnerindicationphaseassetpartnerindicationphaseakcea-ttr-lrxakcatransthyretin amyloydosi rhhbyhuntington biibamyotrop later sclerosi hyperlipidemia nafld/metabol diseas /frontotempor dementia diseas disord hepat chb viru iga neuropathi geograph hepat chb viru metastat head neck domin retin equival balanc oper oper balanc outperform
target price base discount cash flow dcf analysi exhibit
dcf after-tax work cash flow per share discount rate current valu valu valu cash valu rate growth rate
model ten year sale tegsedi waylivra royalti spinraza latin
american sale tegsedi waylivra revenu collabor
assumpt underli price target
tegsedi revenu grow patient
share reach preval popul grow gradual
waylivra eu fc revenu grow
patient share reach waylivra eu fpl label expans
probabl adjust patient share launch grow
outer year
model global royalti grow
base royalti rate assumpt near-term follow declin
longer term driven loss exclus patent expir
royalti revenu latin american sale tegsedi waylivra
 collabor revenu amort up-front payment well
select risk-adjust mileston payment licens fee
combin licens royalti revenu servic revenu
grow annual thereaft
model gross margin wholli own asset outer
year royalti revenu collabor revenu
oper expens consist
sg expens grow thereaft
use net oper loss nol balanc ye carri
forward off-set annual taxabl incom use tax rate
discount cash flow year-end discount rate
believ approxim compani weight averag cost capit base
risk-fre rate expect market return beta per
termin valu growth rate valu attribut termin
estim royaltiestegsediwaylivraamort upfrontmilestone/licensingoth outperform
highli competit market commerci asset
driver valu spinraza tegsedi market increasingli
competit market environ spinraza launch subsequ ionss
royalti stream robust ltm sales/royalti note likelihood
competit time includ novarti zolgensma aav-bas gene therapi
sma patient year age tegsedi could compet alnylam onpattro
us/th eu pfizer vyndaqel eu
theoret estim neg impact price target spinraza royalti
revenu lower base case estim exhibit
tegsedi onpattro target degrad ttr mrna transcript howev
benefits/risk differenti product base administr sub-q vs iv
dose schedul weekli inject vs minut infus everi three week label
tegsedi black box warn rem program requir note efficaci data
product demonstr impact diseas progress exhibit
oppenheim research jame journal neurolog scienc gale adam nejm
ions/akca abil penetr hattr market import driver
valuat theoret estim neg impact valuat tegsedi
revenu lower base case estim exhibit
price revenu basedownsidetegsedionpattrotim assessmentweek measur ls mean chang baselin vs point point qol-dn point point ioni pharmaceut
exhibit tegsedi downsid risk valuat
model payment partner servic provid on-going
basi well option payment mileston licens fee model risk-
adjust mileston licens novarti gsk astrazeneca bayer
astrazeneca roch novarti
revenu includ akcea-apo -lrx licens fee nv licens fee
probability-adjust assumpt payment base develop
phase note may signific variabl q-o-q revenu earn cash
flow base time discretionari natur payment exampl
on-tim achiev assum mileston licens event throughout
project period would theoret add upsid price target failur
ever achiev futur payment would theoret lower price target
price revenu estim amorit up-front paymentsmileston paymentslicens fee servic outperform
probabl adjust base phase develop
assum event achiev posit outcom gener payment
assum event occur/gener payment
stock price compani mention report
manag teamexperi educationstanley crook ph presid smithklin french laboratori us inc chairman board directorsclin fellowship baylor colleg medicinechief execut officerm baylor colleg medicinefounderph baylor colleg medicinebrett monia ph senior editor nucleic acid chief oper officermemb board director dynacur chief execut offic start januari oligonucleotid societysenior vice presid translat medicineadjunct professor biolog san diego state universitymemb board directorsph pharmacolog univers pennsylvaniab molecular biolog analyt chemistri stockton state collegeelizabeth hougenchief account offic ionissenior vice presid financevic presid financ ionischief officerchief offic molecular biosystem inc univers san diegob franklin marshal collegec frank bennett ph advisori board member experiment centr singapor senior vice presid researchadvisori board member hereditari diseas foundationassoci senior investig dept molecular pharmacolog glaxosmithklinepostdoctor research fellow molecular pharmacolog smithklin french laboratoriesph pharmacolog baylor colleg medicineb pharmaci univers new mexico albuquerquerichard geari ph member board director oligonucleotid societysenior vice presid developmentco-lead public committe nucleic acid group leader appli chemistri southwest research institutesenior research scientist appli chemistri southwest research instituteph biopharmaceut univers texa austin biolog texa universitypatrick neil esq associ cooley llp senior vice presid legal gener counselj univers california davi school lawchief complianc officerb busi administr financ univers san francisco ioni pharmaceut
depreci amort
interest incom expens
net incom loss attribut non-controlling interest akcea
net incom loss attribut
revenu
cash equival
properti plant equip net
deposit asset
current portion long-term oblig
current portion defer contract revenu
long-term mortgag debt/financ liabil leas facil
non-controlling interest akcea therapeut
total liabil sharehold equiti
